). This increase in risk was significant in all 4 age groups including the youngest group where atherosclerosis consisted primarily of raised lesions without macroscopic evidence of plaque rupture or thrombosis. Results were similar when we restricted the genetic risk score to 32 single nucleotide polymorphisms not associated with traditional risk factors or when we adjusted for traditional risk factors. Conclusions-A genetic risk score for clinical coronary artery disease is associated with advanced subclinical coronary atherosclerosis throughout the life-course. This association is apparent even at the earliest, uncomplicated stages of atherosclerosis.
G enome-wide association studies (GWAS) over the past ≈8 years have identified 49 susceptibility variants robustly associated with clinically significant complications of coronary artery disease (CAD) including myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, and angina. 1 The mechanisms by which most of these CAD loci influence the risk of clinical CAD remain largely unclear.
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The effect on the risk of clinical CAD for each of these variants is small. However, the effects are independent and additive. Accordingly, the high-risk alleles at the variants can be aggregated into a single predictor of CAD through a multilocus genetic risk score (GRS). [2] [3] [4] Morrison et al 5 were
among the first to illustrate the concept of GRS in the context of predicting CAD before the GWAS era, using single nucleotide polymorphisms (SNPs) within candidate genes. GRSs are now also routinely incorporated into Mendelian randomization studies as powerful instrumental variables that provide important insights on the nature of associations between various human traits. 6, 7 We hypothesized that variants at these loci collectively facilitate the formation of coronary artery plaque throughout the life-course. To test this hypothesis, we investigated the association between a GRS constructed from 49 established susceptibility variants for clinical CAD 1 with the presence of subclinical atherosclerosis among subjects with no history of clinical CAD. Subclinical atherosclerosis was estimated through direct pathological examination of the right coronary Background-Recent genome-wide association studies have identified 49 single nucleotide polymorphisms associated with clinical coronary artery disease. The mechanism by which these loci influence risk remains largely unclear. Methods and Results-We examined the association between a genetic risk score composed of high-risk alleles at the 49 single nucleotide polymorphisms and the degree of subclinical coronary atherosclerosis in 7798 participants from 6 studies stratified into 4 age groups at the time of assessment (15-34, 35-54, 55-74 , and >75 years). Atherosclerosis was quantified by staining and direct visual inspection of the right coronary artery in the youngest group and by scanning for coronary artery calcification in the remaining groups. We defined cases as subjects within the top quartile of degree of atherosclerosis in 3 groups and as subjects with a coronary artery calcium score >0 in the fourth (35-54 years) where less than one quarter had any coronary artery calcium. In our meta-analysis of all strata, we found 1-SD increase in the genetic risk score increased the risk of advanced subclinical coronary atherosclerosis by 36% (P=8.3×10
artery (RCA) in the youngest subjects and through coronary artery calcification scores derived from computed tomography in the remaining subjects. 8 We selected these methods of assessment of subclinical atherosclerosis for 2 reasons. First, coronary artery calcium (CAC) scores are highly correlated with the overall plaque burden in the coronaries. 9 However, the prevalence of CAC is extremely low in subjects under the age of ≈50 years especially women. 10 Second, autopsy studies with direct visualization of coronary plaque provide the best alternative means of assessing the degree of subclinical coronary atherosclerosis in younger subjects. Many such studies have been performed in the past and have established strong correlations between the burden of raised atherosclerotic lesions observed in coronary arteries and the surrounding rates of clinically significant CAD in the community.
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Materials and Methods
Study Population
The older control group in the Atherosclerotic Disease, Vascular Function, and Genetic Epidemiology (ADVANCE) 15 study served as our initial cohort for this analysis. To broaden our range of age at the time of assessment of subclinical atherosclerosis, we extended our analyses to several clinical and genetic data sets available through the National Center for Biotechnology Information database of Genotypes and Phenotypes (dbGAP). 16 These studies included the SNPs and the Extent of Atherosclerosis (SEA) study, an ancillary genetics study of the National Institutes of Health-sponsored Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study, 17 as well as 4 longstanding NHLBI prospective cohort studies: the Coronary Artery Risk Development in Young Adults Study (CARDIA), 18 the Multi Ethnic Study of Atherosclerosis (MESA), 19 the Framingham Heart Study (FHS), 20 and the Cardiovascular Health Study (CHS).
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The Institutional Review Board at Stanford University approved the use of data from dbGAP to conduct this study. Furthermore, an institutional review committee approved each of the 6 studies, and all living subjects gave informed consent. Table I in the Data Supplement lists accession numbers and embargo dates for all dbGAP files used. We stratified subjects within each study into 1 of 4 age groups at the time of assessment of subclinical coronary atherosclerosis (15-34, 35-54, 55-74 , and >75 years). We formed the first age group based on the inclusion criteria for SEA. As the first age stratum included a range of age of 20 years, we selected the next 2 age cutoffs to be at 20-year intervals as well. These cutoffs, while somewhat arbitrary, result in age groups that overlap reasonably well with clinically meaningful onset of disease (ie, premature onset at <35 years of age observed almost exclusively in Mendelian disorders such as familial hypercholesterolemia, early onset between 35 and 55 years of age, typical onset between 56 and 75 years especially for men, and late onset >75 years of age). Because all SNPs to be tested were identified in European and South Asian populations, we restricted our analyses to study participants who self-reported European ancestry.
Phenotype Measurement and Case Definition
The subset of participants from these studies all had either a postmortem pathological determination of the degree of subclinical coronary atherosclerosis (SEA) or an assessment of subclinical coronary atherosclerosis through a CAC study at a point in time when they had no history of clinical CAD (all other studies). Detailed descriptions of the methods used to quantify subclinical atherosclerosis have been previously published. 17, [22] [23] [24] [25] [26] [27] We provide a description of each study focused on the events leading up to participants' assessment for subclinical atherosclerosis and complete details on the methods of assessment of subclinical atherosclerosis in the Data Supplement.
We defined cases within each study and age stratum as those subjects within the stratum that were in the top sex-specific quartile of degree of subclinical atherosclerosis. In SEA, we ranked individual's degree of subclinical atherosclerosis by their sex-specific percent surface area of the RCA affected by raised lesions. We used the RCA because this was the only coronary artery where a global assessment of atherosclerosis extent was calculated. 17 We provide the definition and the characteristics of a raised lesion and a clear justification for selecting this phenotype in SEA over other atherosclerosis phenotypes documented in SEA in the Data Supplement. In the remaining studies, we ranked subjects by their sex-specific CAC score within each age stratum. For both men and women in CARDIA between the ages of 35 to 54 years, and for women in both FHS and MESA between the ages of 35 to 54 years, we defined cases as subjects with a CAC score >0 because the 75% percentile CAC score was still 0 in these strata.
SNP Selection and Imputation
For the construction of the GRS, we selected independent SNPs (LD-pruned, r 2 <0.2) that had reached genome-wide significance at any time during the GWAS era (referred to as either known or novel CAD GWAS SNPs in Table IX in the Data Supplement of the CARDIOGRAMplusC4D article 1 ). Of the 153 low false discovery rate SNPs for CAD in that table, 49 met these criteria. As expected, only a small fraction of the 49 SNPs was genotyped in participants of the 6 studies given the various arrays used. To minimize the need to search for proxies, we used the genotype data within each study to impute additional SNPs. Each study was imputed separately using MaCH (v1.0.18.c) 28 and Minimac software. 29 A 2-stage imputation procedure was followed. First, we used MaCH to phase individuals across chromosome to estimate the haplotypes after first excluding SNPs with minor allele frequency <0.01, Hardy-Weinberg equilibrium P<1×10 −6 , call rate <95%, or large allele frequency discrepancies compared with the 1000 Genomes Project reference data using PLINK. 30 To ensure good quality of phased haplotypes, MaCH was run with the 20 rounds and 200 states for parameter estimation. Then, the phased haplotypes were compared with 1000 Genomes Project haplotypes (version 3 March 2012 release) for imputation using the OpenMP protocol-based multithreaded version of Minimac software with 20 rounds and 300 states for each chromosome.
Construction of the GRS
We calculated a weighted multilocus GRS (wGRSs) for each individual by taking the sum of the products between the dosage of the high-risk alleles at each SNP and its corresponding β coefficient from the CARDIOGRAMplusC4D (Coronary Artery Disease Genome wide Replication and Meta-analysis plus The Coronary Artery Disease consortium) meta-analysis combining stage 1 and 2.
3 An unweighted multilocus GRS was constructed by simply taking the sum of the dosage of high-risk alleles observed at the 49 SNPs. We further calculated a wGRS and GRS restricted to the subset of 32 SNPs not related to traditional risk factors in the assessment of the CARDIoGRAMplusC4D consortium, which reported that 12 of the 49 SNPs were associated with lipids and 5 with blood pressure. 
Statistical Analysis
We used logistic regression to estimate the association between either an SNP or a GRS and case-control status. We adjusted for age and sex in our minimally adjusted models to account for any residual confounding by these variables within an age stratum. In all studies with CAC measures, we ran a second model that further adjusted for the presence of traditional risk factors assessed at the time of scanning including diabetes mellitus, smoking status (current, past, and never), systolic blood pressure, use of antihypertensive drugs, total cholesterol, high-density lipoprotein cholesterol, and use of lipid-lowering agents. Further adjustment in SEA for traditional risk factors was not possible because such data were either not uniformly collected in the original autopsy cohort or not available in dbGAP.
We calculated overall odds ratios (ORs) within each age stratum and across all age strata using random-effects meta-analyses and summarized our results using forest plots. We also calculated I 2 to assess the proportion of observed variance in effect sizes across studies. 31 To ensure that the data from the RCA in the SEA study could be expected to reflect coronary atherosclerosis more generally, we sought external evidence of correlation between the presence of subclinical atherosclerosis in the RCA and the left coronary arteries. First, we calculated the Pearson correlation between the prevalence of raised/fibrous lesions for each 1-cm segment of the 3 arteries in the International Atherosclerosis Project for ≤12 cm from their origin. 32 In addition, we calculated the Pearson correlation coefficients between the CAC scores in the RCA and the Left Main, left anterior descending artery (LAD), and circumflex, respectively, in the CARDIA study.
Results
We analyzed a total of 7798 participants of white/European ancestry from 6 studies covering a broad age range at the time of assessment of subclinical atherosclerosis (18 to >85 years; Table) . Overall, 3539 (45.4%) of all subjects had evidence of subclinical atherosclerosis based on either a percent surface area with raised lesions in the RCA that was >0 or a CAC score that was >0. A subset of 1673 of these 3539 subjects (21% of all subjects) across all cohorts met our case definition.
As expected, the average imputation r 2 for SEA was lower (0.27) than for the other studies (0.87) because it was based on a modest-sized custom SNP array, rather than a full commercial GWAS array (Table) . None of the SNPs showed a significant departure from Hardy-Weinberg equilibrium in any population cohort. The mean wGRS and unweighted GRS involving all 49 SNPs were similar across studies and across age-strata (Table) . Consistent with studies using clinical end points as the outcomes, we found the 2 SNPs in the 9p21 region (rs1333049) to have the strongest association with subclinical disease (rs1333049: OR, 1.45; 95% confidence interval, 1.31-1.61 and rs3217992: OR, 1.27; 95% confidence interval, 1.14-1.40; Table II and Figure I in the Data Supplement). The next strongest signals were for SNPs in the COL4A1/COL4A2 and CXCL12 loci. Associations between risk factors and CAC were as expected (Table III in the Data Supplement).
The wGRS based on all 49 SNPs was strongly associated with subclinical CAD, both before and after adjusting for all traditional risk factors (Figure 1) . The meta-analysis results for our minimally adjusted analysis demonstrates a 36% increase in risk of being a case with each SD increase in the wGRS (P=8.28×10 -25 ). The increase in risk was significant in every age stratum (meta-analysis 0.02>P>1.54×10 −13 ; I 2 = 0%, P for test of heterogeneity=0.89). Results were virtually unchanged after full adjustment for risk factors in the CAC studies. Results were similar when the wGRS was restricted to the 32 nonrisk factor SNPs ( Figure 2 ) and in the corresponding analyses using the unweighted GRS (Figures II and III in the Data Supplement).
In the SEA study, most subjects defined as cases had between 1% and 30% of the surface area of their RCA covered with raised lesions (Figure 3 ). We could not exclude the subset of cases with evidence of more advanced and complex raised lesions because an indicator variable for this phenotype is not available in dbGAP. However, we calculated that not more than 3.9% of the white SEA subjects we studied with raised lesions could have evidence of such lesions (Table IV in the Data Supplement). Figure 4 summarizes the ORs in SEA after applying 3 imputation quality cutoffs (r 2 >0.3, r 2 >0.5, and r 2 >0.8). The strongest association was observed for a cutoff of r 2 >0.3, which allowed for 17 of the 49 SNPs to be used in the construction of the GRS. However, we observed substantial overlap in the confidence intervals of all GRSs (Table V in the Data Supplement). We also observed substantial variability in the imputation quality and the association results for each of the 49 SNPs in SEA (Table VI in the Data Supplement).
We found high correlations between the prevalence of raised/fibrous lesions in the 1-cm segments of the RCA and the LAD (r=0.96; P<0.001), the RCA and the CIRC (r=0.91; P<0.001), and the LAD and the CIRC (r=0.97; P<0.001) in the International Atherosclerosis Project (Table VII in the Data Supplement). We also found high correlations between CAC scores in the RCA and the LAD (r=0.91; P<0.001) as well as the RCA and the CIRC (r=0.94; P<0.001) among CARDIA participants. These high correlations were maintained even when we restricted our analyses to subjects with CAC>0 either in the RCA or in the LAD (Table VIII in the Data Supplement).
Discussion
We found that a multilocus GRS derived from the high-risk alleles of SNPs associated with clinically evident CAD to be strongly associated with the presence of advanced subclinical atherosclerosis. The association was evident starting in young adulthood where subclinical coronary atherosclerosis consists almost exclusively of raised lesions without evidence of plaque rupture or thrombosis. We found the effect estimates to be similar across 4 age groups that spanned almost the entire life-course. Overall, an increase in the GRS by 1 SD was associated with ≈36% increase in the risk of being in the quartile with the highest degree of subclinical coronary atherosclerosis.
Our findings were consistent in 3 sets of sensitivity analyses. First, we repeated all analyses after removing from the 17 SNPs from the GRS that are most likely influencing clinical CAD through effects on traditional risk factors, 1 and we ran secondary models adjusting for all traditional risk factors for CAD. We performed these sensitivity analyses to ensure that the associations observed were not being driven by traditional risk factors. Dyslipidemia, in particular, has already been unequivocally linked to the rate of development of subclinical atherosclerosis both in human and in animal studies. [33] [34] [35] [36] We found that the strength of the associations overall and within each age stratum persists even after full adjustment. The reason for this persistence is unclear but is consistent with previous studies testing the same (or similar) GRS for association with clinical end points. 2, 3, 37 One possibility is that risk factor SNPs retain the ability to predict CAD outcomes even after adjusting for a single measure of the risk factors because of the phenomenon of regression dilution. 38 Our second sensitivity analysis explored the effects of weighting the GRS. We found that weighting increased the overall effect size and the statistical significance of the association between our GRS and subclinical CAD. On the contrary, weighting led to a minimal increase in the heterogeneity for the 32 SNP GRS manifested by a lower but still nonsignificant P value for the test of heterogeneity.
Our third sensitivity analysis was focused on SEA. This study was unique because of not only the method of assessment of subclinical atherosclerosis but also the genotyping platform used, which consisted of an early Perlegen GWAS array that included only ≈106 000 SNPs. Only approximately two thirds of the SNPs genotyped using this platform passed our standard preimputation quality control. Consequently, the mean imputation quality for SEA was significantly lower than all other studies. In the 4 models we tested, we invariably found the highest point estimates and the lowest P values for the analyses that restricted the GRS to the subset of SNPs with an imputation r 2 >0.3 although these differences were not large when compared with the models that used all 49 SNPs. Imposing an even higher imputation score threshold led to a further substantial restriction of SNPs and a degradation of the association signal. The relatively large difference in the OR for the 2 GRS models restricted to the small number SNPs with high imputation quality (r 2 >0.8) is likely a consequence of the removal of rs6544713, an SNP associated with LDL that coincidentally also has one the best combinations of imputation quality, magnitude of effect, and strength of association in the SEA study. Collectively, these circumstances and observations suggest that the OR for the GRS in SEA may represent a substantial underestimate of the true OR because of extensive misclassification of the genotype in both cases and controls. Additional genotyping of the PDAY cohort could provide evidence in support or against this possibility.
Our study had 3 additional limitations worthy of mention. First, we were unable to anatomically match the assessment of subclinical coronary atherosclerosis across all studies because the SEA study was restricted to the RCA, and the other studies assessed the degree of subclinical atherosclerosis in all 3 coronary arteries combined. However, we provide evidence of a high correlation of subclinical disease between arteries assessed directly or through CAC scanning. Additional evidence of a semiquantitative nature for a high correlation between the presence of raised lesions in the RCA and the left coronary artery is provided by the World Health Organization study in 5 European towns. 39 Second, we had more limited power to detect associations in the extreme age strata where overall number of subjects available for study was lower. Nevertheless, we observed nominally significant associations in these age strata in our main analysis and most of our sensitivity analyses. Third, the identification of the quartile of subjects with the highest degree of subclinical atherosclerosis in the age stratum of 35 to 54 age strata was hampered by a low overall prevalence of subjects with any CAC. Thus, the percent of subjects with CAC>0 was less than 25% and the size of the case group ranged from 12.7% to 20.3%. The ORs of association in these strata may be biased toward the null because the control group includes some subjects with more advanced but noncalcified plaque. A possible underestimate of the OR in this age range combined with a possible underestimate of the OR in SEA may be one reason we observe a fairly homogeneous association across age groups. Conversely, the sampling of extremes in PDAY by SEA investigators may have biased the OR upward, but we suspect that such a selection bias is likely small in comparison with that related to poor imputation.
Our findings have several implications. First, they are consistent with the hypothesis that susceptibility loci for CAD discovered to date through GWAS predispose an individual to clinical complications of CAD from birth primarily through the modulation of the rate of formation of coronary plaque. This predisposition becomes apparent early in life and continues throughout one's life-course with evidence of predisposition persistent into the ninth decade of life. However, the cross-sectional nature of our analyses combined with the possible biased estimates of effect in our youngest age groups does not allow us to conclude with certainty whether this predisposition is causally operative at all ages. For example, it is possible that the GRS predisposes only to early lesions and then has no further impact over the life-course. Second, our observations raise the possibility that the genetic risk associated with GWAS loci for clinical CAD may not involve a specific predisposition to intraplaque rupture, intraluminal plaque rupture, or thrombosis given that it appears at a very young age when plaques are generally too small to be prone to these structural complications. 40, 41 This hypothesis is best supported by the associations we observed in SEA, which were largely driven by the presence of early-stage, minimally raised, and uncomplicated atherosclerotic lesions involving the RCA. We acknowledge that it is difficult to prove that this hypothesis based solely on our observations as we did not directly examine these plaque phenotypes. Furthermore, we cannot rule out the possibility of atherosclerosis progression through either plaque fissuring with thrombus incorporation or intralesional hemorrhage within the early-stage lesions observed in PDAY. However, multiple previous autopsy studies suggest that such events are extremely rare among the Stary Type IV and V lesions observed in the PDAY/SEA study. [11] [12] [13] [14] 40, 41 Finally, our findings bolster previous observations from several epidemiological studies demonstrating CAC to be a strong independent predictor of incident clinical CAD. 42 We note 2 reasons why contemporary GWAS of clinical CAD may be at a disadvantage in identifying loci that specifically predispose to plaque rupture or thrombosis. First, such studies are hampered by the possibility that a sizable fraction of all controls is actually not at risk of rupture and thrombosis 2 ) in SEA of the SNPs included in the weighted genetic risk score (GRS). A higher imputation r 2 threshold indicates more reliable imputation of genotypes. The number of SNPs included in the GRS at a given imputation threshold is included within brackets. GRS49 begins with all 49 SNPs associated with clinical coronary artery disease (CAD) in the CARDIoGRAMplusC4D (Coronary Artery Disease Genome wide Replication and Metaanalysis plus The Coronary Artery Disease Genetics) study, whereas GRS32 begins with the subset of SNPs that are not associated with traditional risk factors of CAD. December 2015 because they possess a low burden of atherosclerosis as suggested by a CAC score of 0 (Table) . [43] [44] [45] Second, the rate of misclassification of controls may be high even in studies where the burden of atherosclerosis is better matched between cases and controls (eg, comparing control subjects with CAD and no myocardial infarction to case subjects with CAD and myocardial infarction) because many controls may have still experienced subclinical plaque ruptures or thrombosis. [46] [47] [48] In conclusion, we have shown that risk alleles for clinical CAD are collectively associated with subclinical atherosclerosis throughout the life course. This association is not driven by alleles that are associated with traditional risk factors and it is apparent even at the earliest, uncomplicated stages of atherosclerosis. We found that the magnitude of this association to be homogenous across age groups although we may have substantially underestimated it in the younger age groups because of technical limitations. Our observations suggest that susceptibility loci for CAD discovered to date predispose to clinical complications of CAD predominantly by promoting the formation of coronary plaque. However, additional population genetic and mechanistic studies are warranted to further test this hypothesis.
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